NCT04664829View on ClinicalTrials.gov

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

August 4, 2025

Study Completion Date

August 4, 2025

Conditions
Metastatic Triple-Negative Breast Carcinoma
Interventions
DRUG

Bexarotene

Administered orally once a day. Starting dosage: 200mg/m\^2

DRUG

Capecitabine

Administered orally twice a day. Dosage: 1000mg/m\^2

Trial Locations (1)

168583

National Cancer Center Singapore, Singapore

All Listed Sponsors
collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

National Cancer Centre, Singapore

OTHER

NCT04664829 - The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC | Biotech Hunter | Biotech Hunter